PGEN
Precigen, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.10
−0.56%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
14.6x
EV/EBITDA
−18.0x
Market Cap
$2.54B
MomentumView details →
1D Return
−0.56%
YTD Return
+70.69%
RSI (14)
58.7
ValuationView details →
P/E (Fwd)
14.6x
EV/EBITDA
−18.0x
Market Cap
$2.54B
RSI (14)
58.7
MomentumView details →
1D Return
−0.56%
YTD Return
+70.69%
SummaryUpdated Jun 1, 2026
Precigen, Inc. (NASDAQ:PGEN) is a biotechnology company founded in 1998 and headquartered in Germantown, Maryland. Originally known as Intrexon Corporation, the company rebranded to Precigen in January 2020 to better reflect its focus on precision gene and cellular therapies. The company has evolved from a broader synthetic biology platform into a specialized developer of next-generation gene and cellular therapies, with particular emphasis on rare diseases and cancer treatments. Precigen has undergone significant strategic restructuring in recent years, streamlining operations to focus on its most promising therapeutic candidates while divesting non-core assets.
Similar companies
Latest newsMore news →
Jeffrey B. Kindler, a director at Precigen, Inc., sold 185,000 shares of the company's common stock on August 26, 2026, for a total value of $1,376,400.7d agoPrecigen Inc. reported second-quarter net product revenue of $53.1 million for PAPZIMEOS, more than double the prior quarter, and achieved quarterly profitability.11d agoPrecigen reported second quarter 2026 financial results, with PAPZIMEOS net revenue of $53.1 million and quarterly profitability, and cash totaling $38.7 million as of June 30, 2026.31d ago